XTALPI (02228) saw its shares rise more than 8% during the morning session. At the time of writing, the stock was up 6.98%, trading at HK$10.12 with a turnover of HK$129 million. Last month, Mirxes, a company focused on early cancer screening, announced a collaboration with AI pharmaceutical platform firm XTALPI. The partnership aims to leverage their respective strengths in early detection and drug research and development to jointly explore integrated "diagnosis and treatment" solutions for cancers highly prevalent in Asia. This move is viewed as a significant attempt to consolidate the value chain in cancer prevention and control. Shenwan Hongyuan released a research report stating that XTALPI, built upon its core technologies of "physics computation + AI + robotics," has established a complete closed-loop system for early-stage drug discovery, spanning from algorithms and engines to automated laboratories. The company's business has successfully expanded from AI-driven drug discovery to the broader "AI4S" platform. Its underlying technology not only accelerates various stages of innovative drug development but also holds the potential for application in new materials and other fields, demonstrating substantial technical breadth and platform value. The firm initiated coverage with a "Buy" rating.